{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:16:58Z","timestamp":1767374218132,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The DNA-damaging compound cisplatin is broadly employed for cancer chemotherapy. The mutagenic effects of cisplatin on cancer cell genomes are poorly studied and might even contribute to drug resistance. We have therefore analyzed mutations and chromosomal alterations in four cisplatin-resistant bladder cancer cell lines (LTTs) by whole-exome-sequencing and array-CGH. 720\u20137479 genes in the LTTs contained point mutations, with a characteristic mutational signature. Only 53 genes were mutated in all LTTs, including the presumed cisplatin exporter <jats:italic>ATP7B<\/jats:italic>. Chromosomal alterations were characterized by segmented deletions and gains leading to severely altered karyotypes. The few chromosomal changes shared among LTTs included gains involving the anti-apoptotic <jats:italic>BCL2L1<\/jats:italic> gene and losses involving the NRF2 regulator <jats:italic>KEAP1<\/jats:italic>. Overall, the extent of genomic changes paralleled cisplatin treatment concentrations. In conclusion, bladder cancer cell lines selected for cisplatin-resistance contain abundant and characteristic drug-induced genomic changes. Cisplatin treatment may therefore generate novel tumor genomes during patient treatment.<\/jats:p>","DOI":"10.1038\/s41598-019-50891-w","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T11:25:52Z","timestamp":1570620352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2152-384X","authenticated-orcid":false,"given":"Margaretha A.","family":"Skowron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-5524","authenticated-orcid":false,"given":"Patrick","family":"Petzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Hardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4192-4774","authenticated-orcid":false,"given":"Nicholas","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Beier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9457-6929","authenticated-orcid":false,"given":"Stefanie","family":"Stepanow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Drechsler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Rieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-2022","authenticated-orcid":false,"given":"Karl","family":"K\u00f6hrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-8691","authenticated-orcid":false,"given":"G\u00fcnter","family":"Niegisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6044-1671","authenticated-orcid":false,"given":"Mich\u00e8le J.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2196-463X","authenticated-orcid":false,"given":"Wolfgang A.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,9]]},"reference":[{"key":"50891_CR1","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat, A. M. et al. Bladder cancer. Lancet 388, 2796\u20132810, https:\/\/doi.org\/10.1016\/S0140-6736(16)30512-8 (2016).","journal-title":"Lancet"},{"key":"50891_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"S Antoni","year":"2017","unstructured":"Antoni, S. et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 71, 96\u2013108, https:\/\/doi.org\/10.1016\/j.eururo.2016.06.010 (2017).","journal-title":"Eur Urol."},{"key":"50891_CR3","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay, J. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136, E359\u2013E386, https:\/\/doi.org\/10.1002\/ijc.29210 (2015).","journal-title":"Int J Cancer."},{"key":"50891_CR4","doi-asserted-by":"publisher","first-page":"41320","DOI":"10.18632\/oncotarget.9321","volume":"7","author":"A H\u00f6hn","year":"2016","unstructured":"H\u00f6hn, A. et al. Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells. Oncotarget. 7, 41320\u201341335, https:\/\/doi.org\/10.18632\/oncotarget.9321 (2016).","journal-title":"Oncotarget."},{"key":"50891_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13046-015-0259-x","volume":"34","author":"MA Skowron","year":"2015","unstructured":"Skowron, M. A. et al. Phenotype plasticity rather than repopulation from CD90\/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines. J Exp Clin Cancer Res. 34, 144, https:\/\/doi.org\/10.1186\/s13046-015-0259-x (2015).","journal-title":"J Exp Clin Cancer Res."},{"key":"50891_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.11.021","author":"D Schlutermann","year":"2017","unstructured":"Schlutermann, D. et al. Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex. Urol Oncol. https:\/\/doi.org\/10.1016\/j.urolonc.2017.11.021 (2017).","journal-title":"Urol Oncol."},{"key":"50891_CR7","doi-asserted-by":"publisher","unstructured":"Skowron, M. A. et al. Multifaceted mechanisms of cisplatin resistance in long-term treated urothelial carcinoma cell lines. Int J Mol Sci. 19, https:\/\/doi.org\/10.3390\/ijms19020590 (2018).","DOI":"10.3390\/ijms19020590"},{"key":"50891_CR8","doi-asserted-by":"publisher","unstructured":"Skowron, M. A. et al. Various mechanisms involve the nuclear factor (erythroid-derived 2)-like (NRF2) to achieve cytoprotection in long-term cisplatin-treated urothelial carcinoma cell lines. Int J Mol Sci 18 https:\/\/doi.org\/10.3390\/ijms18081680 (2017).","DOI":"10.3390\/ijms18081680"},{"key":"50891_CR9","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/Onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi, L. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869\u20131883, https:\/\/doi.org\/10.1038\/Onc.2011.384 (2012).","journal-title":"Oncogene"},{"key":"50891_CR10","doi-asserted-by":"crossref","unstructured":"K\u00f6berle, B. & Piee-Staffa, A. The molecular basis of cisplatin resistance in bladder cancer cells. In Bladder Cancer - From Basic Science to Robotic Surgery (ed. Canda, A. E.) Ch. 13, 265\u2013290 (InTech, 2012).","DOI":"10.5772\/27073"},{"key":"50891_CR11","doi-asserted-by":"publisher","first-page":"14246","DOI":"10.1002\/anie.201607380","volume":"55","author":"X Shu","year":"2016","unstructured":"Shu, X., Xiong, X., Song, J., He, C. & Yi, C. Base-resolution analysis of cisplatin-DNA adducts at the genome scale. Angew Chem Int Ed Engl. 55, 14246\u201314249, https:\/\/doi.org\/10.1002\/anie.201607380 (2016).","journal-title":"Angew Chem Int Ed Engl."},{"key":"50891_CR12","doi-asserted-by":"crossref","unstructured":"Wozniak, K. & Blasiak, J. Recognition and repair of DNA-cisplatin adducts. Acta Biochim Pol. 49, 583\u2013596, 024903583 (2002).","DOI":"10.18388\/abp.2002_3768"},{"key":"50891_CR13","doi-asserted-by":"publisher","DOI":"10.1101\/gr.230219.117","author":"A Boot","year":"2018","unstructured":"Boot, A. et al. In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors. Genome Res. https:\/\/doi.org\/10.1101\/gr.230219.117 (2018).","journal-title":"Genome Res."},{"key":"50891_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2999-1","volume":"17","author":"IA Cree","year":"2017","unstructured":"Cree, I. A. & Charlton, P. Molecular chess? Hallmarks of anti-cancer drug resistance. BMC Cancer 17, 10, https:\/\/doi.org\/10.1186\/s12885-016-2999-1 (2017).","journal-title":"BMC Cancer"},{"key":"50891_CR15","doi-asserted-by":"publisher","first-page":"D750","DOI":"10.1093\/nar\/gkp889","volume":"38","author":"R Milo","year":"2010","unstructured":"Milo, R., Jorgensen, P., Moran, U., Weber, G. & Springer, M. BioNumbers\u2013the database of key numbers in molecular and cell biology. Nucleic Acids Res. 38, D750\u2013753, https:\/\/doi.org\/10.1093\/nar\/gkp889 (2010).","journal-title":"Nucleic Acids Res."},{"key":"50891_CR16","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1016\/j.febslet.2010.10.029","volume":"584","author":"F Tadini-Buoninsegni","year":"2010","unstructured":"Tadini-Buoninsegni, F. et al. ATP dependent charge movement in ATP7B Cu+-ATPase is demonstrated by pre-steady state electrical measurements. FEBS Lett 584, 4619\u20134622, https:\/\/doi.org\/10.1016\/j.febslet.2010.10.029 (2010).","journal-title":"FEBS Lett"},{"key":"50891_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44\u201357, https:\/\/doi.org\/10.1038\/nprot.2008.211 (2009).","journal-title":"Nat Protoc"},{"key":"50891_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/gcc.20166","volume":"43","author":"SV Williams","year":"2005","unstructured":"Williams, S. V. et al. Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro. Genes Chromosomes Cancer. 43, 315\u2013328, https:\/\/doi.org\/10.1002\/gcc.20166 (2005).","journal-title":"Genes Chromosomes Cancer."},{"key":"50891_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature. 500, 415\u2013421, https:\/\/doi.org\/10.1038\/nature12477 (2013).","journal-title":"Nature."},{"key":"50891_CR20","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ng.3557","volume":"48","author":"J Kim","year":"2016","unstructured":"Kim, J. et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet 48, 600\u2013606, https:\/\/doi.org\/10.1038\/ng.3557 (2016).","journal-title":"Nat Genet"},{"key":"50891_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02320-7","volume":"8","author":"D Liu","year":"2017","unstructured":"Liu, D. et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 8, 2193, https:\/\/doi.org\/10.1038\/s41467-017-02320-7 (2017).","journal-title":"Nat Commun."},{"key":"50891_CR22","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/ng.3692","volume":"48","author":"BM Faltas","year":"2016","unstructured":"Faltas, B. M. et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet 48, 1490\u20131499, https:\/\/doi.org\/10.1038\/ng.3692 (2016).","journal-title":"Nat Genet"},{"key":"50891_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0963-7","volume":"17","author":"B Szikriszt","year":"2016","unstructured":"Szikriszt, B. et al. A comprehensive survey of the mutagenic impact of common cancer cytotoxics. Genome Biol 17, 99, https:\/\/doi.org\/10.1186\/s13059-016-0963-7 (2016).","journal-title":"Genome Biol"},{"key":"50891_CR24","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1101\/gr.175547.114","volume":"24","author":"B Meier","year":"2014","unstructured":"Meier, B. et al. C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency. Genome Res. 24, 1624\u20131636, https:\/\/doi.org\/10.1101\/gr.175547.114 (2014).","journal-title":"Genome Res."},{"key":"50891_CR25","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1073\/pnas.1618555114","volume":"114","author":"R Segovia","year":"2017","unstructured":"Segovia, R., Shen, Y., Lujan, S. A., Jones, S. J. & Stirling, P. C. Hypermutation signature reveals a slippage and realignment model of translesion synthesis by Rev3 polymerase in cisplatin-treated yeast. Proc Natl Acad Sci USA 114, 2663\u20132668, https:\/\/doi.org\/10.1073\/pnas.1618555114 (2017).","journal-title":"Proc Natl Acad Sci USA"},{"key":"50891_CR26","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.18632\/oncotarget.23344","volume":"9","author":"AP Glaser","year":"2018","unstructured":"Glaser, A. P. et al. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response. Oncotarget 9, 4537\u20134548, https:\/\/doi.org\/10.18632\/oncotarget.23344 (2018).","journal-title":"Oncotarget"},{"key":"50891_CR27","doi-asserted-by":"publisher","unstructured":"Jaguva Vasudevan, A. et al. APOBEC3B activity is prevalent in urothelial carcinoma cells and only slightly affected by LINE-1 expression Front. Microbiol. 9:2088 https:\/\/doi.org\/10.3389\/fmicb.2018.02088 (2018).","DOI":"10.3389\/fmicb.2018.02088"},{"key":"50891_CR28","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000108297","volume":"118","author":"K Neveling","year":"2007","unstructured":"Neveling, K. et al. Disruption of the FA\/BRCA pathway in bladder cancer. Cytogenet Genome Res. 118, 166\u2013176, https:\/\/doi.org\/10.1159\/000108297 (2007).","journal-title":"Cytogenet Genome Res."},{"key":"50891_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00204-008-0280-3","volume":"82","author":"AR Florl","year":"2008","unstructured":"Florl, A. R. & Schulz, W. A. Chromosomal instability in bladder cancer. Arch Toxicol. 82, 173\u2013182, https:\/\/doi.org\/10.1007\/s00204-008-0280-3 (2008).","journal-title":"Arch Toxicol."},{"key":"50891_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mrfmmm.2007.08.016","volume":"638","author":"F Windhofer","year":"2008","unstructured":"Windhofer, F., Krause, S., Hader, C., Schulz, W. A. & Florl, A. R. Distinctive differences in DNA double-strand break repair between normal urothelial and urothelial carcinoma cells. Mutat Res. 638, 56\u201365, https:\/\/doi.org\/10.1016\/j.mrfmmm.2007.08.016 (2008).","journal-title":"Mutat Res."},{"key":"50891_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/Nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15, 25\u201341, https:\/\/doi.org\/10.1038\/Nrc3817 (2015).","journal-title":"Nat Rev Cancer"},{"key":"50891_CR32","first-page":"3731","volume":"33","author":"SC Schmid","year":"2013","unstructured":"Schmid, S. C. et al. Utility of ATP7B in prediction of response to platinum-based chemotherapy in urothelial bladder cancer. Anticancer Res 33, 3731\u20133737 (2013).","journal-title":"Anticancer Res"},{"key":"50891_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1515\/hsz-2017-0184","volume":"399","author":"S Lorenz","year":"2018","unstructured":"Lorenz, S. Structural mechanisms of HECT-type ubiquitin ligases. Biol Chem 399, 127\u2013145, https:\/\/doi.org\/10.1515\/hsz-2017-0184 (2018).","journal-title":"Biol Chem"},{"key":"50891_CR34","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1038\/sj.onc.1211032","volume":"27","author":"Y Li","year":"2008","unstructured":"Li, Y. et al. A novel HECT-type E3 ubiquitin protein ligase NEDL1 enhances the p53-mediated apoptotic cell death in its catalytic activity-independent manner. Oncogene 27, 3700\u20133709, https:\/\/doi.org\/10.1038\/sj.onc.1211032 (2008).","journal-title":"Oncogene"},{"key":"50891_CR35","doi-asserted-by":"crossref","unstructured":"McGowan-Jordan, J., Simons, A. & Schmid, M. ISCN 2016 - An International System for Human Cytogenomic Nomenclature. (S. Karger Publishing, 2016).","DOI":"10.1159\/isbn.978-3-318-06861-0"},{"key":"50891_CR36","unstructured":"R-Core-Team. R: A language and environment for statistical computing - R Foundation for Statistical Computing, https:\/\/www.R-project.org (2016)."},{"key":"50891_CR37","unstructured":"Seshan, V. E. & Olshen, A. DNAcopy: DNA copy number data analysis. R package version 1.46.0., https:\/\/bioconductor.org\/packages\/release\/bioc\/html\/DNAcopy.html (2016)."},{"key":"50891_CR38","unstructured":"Hupe, P. GLAD: Gain and loss analysis of DNA. R package version 2.36.0., http:\/\/bioinfo.curie.fr (2011)."},{"key":"50891_CR39","unstructured":"Ben-Yaacov, E. & Eldar, Y. C. HaarSeg: HaarSeg. R package version 0.0.3\/r4, https:\/\/R-Forge.R-project.org\/projects\/haarseg (2009)."},{"key":"50891_CR40","doi-asserted-by":"publisher","first-page":"i139","DOI":"10.1093\/bioinformatics\/btn272","volume":"24","author":"E Ben-Yaacov","year":"2008","unstructured":"Ben-Yaacov, E. & Eldar, Y. C. A fast and flexible method for the segmentation of aCGH data. Bioinformatics 24, i139\u2013145, https:\/\/doi.org\/10.1093\/bioinformatics\/btn272 (2008).","journal-title":"Bioinformatics"},{"key":"50891_CR41","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cell.2012.04.024","volume":"149","author":"S Nik-Zainal","year":"2012","unstructured":"Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 149, 979\u2013993, https:\/\/doi.org\/10.1016\/j.cell.2012.04.024 (2012).","journal-title":"Cell."},{"key":"50891_CR42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.gde.2013.11.014","volume":"24","author":"LB Alexandrov","year":"2014","unstructured":"Alexandrov, L. B. & Stratton, M. R. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev. 24, 52\u201360, https:\/\/doi.org\/10.1016\/j.gde.2013.11.014 (2014).","journal-title":"Curr Opin Genet Dev."},{"key":"50891_CR43","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1093\/bioinformatics\/btv408","volume":"31","author":"JS Gehring","year":"2015","unstructured":"Gehring, J. S., Fischer, B., Lawrence, M. & Huber, W. SomaticSignatures: inferring mutational signatures from single-nucleotide variants. Bioinformatics. 31, 3673\u20133675, https:\/\/doi.org\/10.1093\/bioinformatics\/btv408 (2015).","journal-title":"Bioinformatics."},{"key":"50891_CR44","unstructured":"Ahmed, A. Cosine Similarity Calculator, http:\/\/scistatcalc.blogspot.com\/2015\/11\/cosine-similarity-calculator.html (2015)."},{"key":"50891_CR45","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404, https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095 (2012).","journal-title":"Cancer Discov."},{"key":"50891_CR46","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6, pl1, https:\/\/doi.org\/10.1126\/scisignal.2004088 (2013).","journal-title":"Sci Signal."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-50891-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-50891-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-50891-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T14:23:46Z","timestamp":1671287026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-50891-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,9]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["50891"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-50891-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2019,10,9]]},"assertion":[{"value":"13 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14476"}}